Information Provided By: 
Fly News Breaks for May 15, 2018
LIFE
May 15, 2018 | 05:37 EDT
Citi analyst Joel Beatty last night downgraded aTyr Pharma to Sell from Neutral and cut his price target to $1 from $4. A lack of clinical data and early stage of understanding for lead agent ATYR1923 create a low probability of success, Beatty told investors in a research note. aTyr yesterday announced the end of its preclinical ORCA program due to lack of sufficient efficacy as well as a 30% workforce reduction.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
